A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease. |
| |
| Authors: | Douglas W Scharre Rebecca A Davis Jennifer L Warner Shu-Ing Chang David Q Beversdorf |
| |
| Affiliation: | Division of Cognitive Neurology, Department of Neurology, The Ohio State University, Columbus, OH 43210, USA. scharre.1@osu.edu |
| |
| Abstract: | OBJECTIVE: In a prospective, open-label pilot study in probable-Alzheimer disease (AD) outpatients, the authors investigated the efficacy of citalopram to reduce restless activity and aberrant motor behaviors. METHODS: Nineteen subjects were evaluated with Neuropsychiatric Inventory subscale and total scores. RESULTS: There was a significant decline in aberrant motor behaviors and overall behavior problems at 4, 8, and 12 weeks. CONCLUSION: This study provides initial evidence that citalopram may be effective in reducing aberrant motor behaviors in AD. However, because of the potential biases of an open-label study, these findings need to be confirmed in a larger, controlled trial. |
| |
| Keywords: | |
|
|
